ESTRO 2024 - Abstract Book

S1532

Clinical - Lower GI

ESTRO 2024

Conclusion:

This is the largest cohort of patients with primary or recurrent PDAC that received treatment on a 1.5T MR-Linac. Without grade 4 toxicity and a maximum grade 3 toxicity rate of 1.9%, toxicity is suggested to be acceptable. Patient-reported outcomes were either not impacted or only during a short term. Updated results will be presented during ESTRO 2024.

Keywords: MR-guided radiotherapy, pancreatic cancer

References:

1. Henke L, Kashani R, Robinson C, Curcuru A, DeWees T, Bradley J, Green O, Michalski J, Mutic S, Parikh P, Olsen J. Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen. Radiother Oncol. 2018 Mar;126(3):519 526. doi: 10.1016/j.radonc.2017.11.032. Epub 2017 Dec 23. PMID: 29277446. 2. Eijkelenkamp H, Grimbergen G, Daamen LA, Heerkens HD, van de Ven S, Mook S, Meijer GJ, Molenaar IQ, van Santvoort HC, Paulson E, Erickson BA, Verkooijen HM, Hall WA, Intven MPW. Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac. Front Oncol. 2023 Oct 3;13:1040673. doi: 10.3389/fonc.2023.1040673. PMID: 37854684; PMCID: PMC10579578.